ghostery.comThe average age of patients in the study, 23, did not represent the population likely to take the drug, he added. Because of confidentiality rules, the F.D.A. Yet through publication in the leading dental journal, the research helped Bextra's marketers shift attention away from the F.D.A.'s negative findings. SRC:MixSentence, IDs:1CB5D976;485FA936;3AD5669B;AF24C528;430C4AF5;DE757C7F;4F45A2FE;24F2A662;99219F16;FC8C0D50;63624C40;F78D37A9;1F46BF33;4F03F29E;C54A2492;1FADB78C;0ECB4049;04EFBA12;6B520626;E73F66B8;EA15627F;F3096291;39C9A45B;CEC0943E;C0692D6E;48263096;62457DA4
If this is where clinical research is headed, that would be a terrible negative trajectory," he said. cannot release any information about the earlier pain studies that failed to sway regulators. Pharmacia was not trying to bypass the regulatory process, she said, adding that the company is in discussions with regulators to have Bextra approved for acute pain. "Even though the study lacked some important proof, the real problem is that in the dental literature, this will be read," Dr. "And dentists, who have to deal with trying to prevent or modulate pain, will be impressed." Judy Glova, a spokeswoman for Pharmacia, said the drug company stood behind the design and conclusions of the Scirex studies. Editors at The Journal of the American Dental Association said the Scirex article was reviewed by at least three scientists. Topol - who drew attention last year with a finding that Celebrex and its competitor, Vioxx, appeared to raise the risk of heart attacks - said the Bextra studies did not include enough patients to justify drawing a broad conclusion. Moore said he would have recommended that the journal reject the paper had he known that Bextra was not approved for acute pain. In the early 1990's, about 75 percent of the drug industry's clinical research dollars went to universities, according to a study by CenterWatch, a company that tracks clinical trials. Omnicom says it has no control over Scirex. Scirex executives did not return repeated phone calls. Yet when the ad agency paid $20 million for part-ownership of Scirex in 1999, a top Omnicom executive, Thomas L. The Bextra episode is just one example of the changing face of drug research. By 2000, just 34 percent went to academic institutions, while the rest went to investigators working under the direction of either a private research firm like Scirex or a pharmaceutical company. Moore, an associate editor of the journal, said the study was "carefully designed and rigorously performed." But Dr. "Our goal," he said, "is to help ensure that all clinical studies and each patient accrued into a study can be assessed to support the N.D.A. "We have nothing to do with the design of clinical studies," said Pat Sloan, an Omnicom spokeswoman. In case you loved this short article in addition to you wish to obtain more information regarding Help guide kindly check out our own web-page. Harrison, said he expected Scirex's research to produce positive results for drug company clients - results that would help speed new-drug applications, or N.D.A.'s, to the F.D.A.

"But, of course, inferences can be made." One such "potential theoretical conclusion" of the article, Ms. We would like to help draft this manuscript," Marcia Zabusky, a vice president of Intramed, told the doctors in a conference call, according to a transcript of the conversation obtained by The New York Times, "and then submit it to you for your - for your editing and for approval." During the call, Shane Schaffer, a Novartis marketing executive, told the doctors that the company wanted "a quick, down and dirty" article. Markowitz and Kennerly S. Patrick of the Medical University of South Carolina - agreed to what Intramed and Novartis proposed. SRC:MixSentence, IDs:4F45A2FE;8E020393;430C4AF5;D7418648;029700BB;3AD5669B;CEC0943E;5E804A06;2C342F27;6B520626;EA73E075;F7F7F036;167CCA31;FEE5A7E4;AF24C528;07405E10;FDCAA27E;F1FE3AF6;F4EC029B;CC2BCDF5;49E5C53D;CE505E59;A29C6F39;103B5D06;878FED22;63624C40;03D22A85
"The time it takes for a new technology to be adopted by 50 percent of US households has long been used by economic historians for cross-technology comparisons. Patrick said as the call concluded. To produce the new article draft, Intramed turned to Linda Logdberg, who has a doctorate in anatomy and has made her living the last 12 years as a ghostwriter for Intramed and other medical marketing companies. Starting with an outline approved by Intramed, Dr. "Obviously, we have to stick within data limits of what's published currently as well as what we know are factual about these products," he told the doctors. Logdberg said that she produced a new manuscript in a few days. A study expected to provide scientific data showing Ritalin LA's advantages was not scheduled to start until the following day, he said, but the lack of research findings should not be an obstacle. The assignment was one of her last ghostwriting tasks. Typically, she said, her manuscript would be sent to the drug company for approval before it was given to the doctors who were paid to be listed as the authors. Logdberg, who recently took a job teaching biology to high school students, said that she had become increasingly disenchanted with the process. The marketing companies, she added, "will drop a doctor if they don't think he will be particularly malleable." The result, Dr. Logdberg said, while others made no changes at all. Some doctors fretted over each comma, Dr. "I think we're quite clear on what you want the next manuscript to look like," Dr. Beitler, chairman of Sudler & Hennessey, a division at WPP that includes Intramed. Zabusky added, was that a drug that worked for 9 hours might be better than a 12-hour drug. "The doctors are the ultimate writers." Dr. "What I mind is advertising that calls itself education." The ad agencies' medical education companies say that they neither toy with science nor ghostwrite articles that physicians use to make decisions about prescribing drugs. "No figure, no table, anything goes in without our approval," Dr. Neither the doctors nor the companies disputed the accuracy of the transcript of their conference call. Patrick added that he thought, based on past research, that a drug like Ritalin LA could be better for certain children than other long-lasting drugs. Novartis said the article was not intended to conclude that one product was better than the others. Logdberg said, is marketing masquerading as science. Patrick agreed, saying that Intramed did not dictate what their paper should say. The article has not been published. Beitler said that Intramed was unhappy with the manuscript that Dr. Logdberg produced and later gave the assignment to another writer. Wyeth hired ghostwriters in promoting the diet drug combination fen-phen, according to documents made public in litigation filed after it became evident that fen-phen caused a potentially deadly heart-valve defect. "We make editorial suggestions," said Jed A. One document made public in a whistle-blower lawsuit against Warner-Lambert describes how Proworx, a company owned by the ad giant Omnicom, offered to help write journal articles about using Neurontin to treat pain. Proworx planned to recruit doctors to be the named authors of the articles, paying them a $1,500 fee. Omnicom declined to comment on the matter. A 1998 survey of named authors writing for some of the nation's top journals, including The Journal of the American Medical Association, which published the survey, found that 11 percent of the articles had been ghostwritten. "We don't get anywhere in medicine without objective data," he said. Instead, the company said, it was a review of the available medications in which the authors could suggest theoretical advantages. Relman, the former editor of The New England Journal of Medicine, said there was no place in medical education for ad agencies. "That's the coin of the realm. Evidence of ghostwriting has also surfaced in federal and state investigations of Warner-Lambert's marketing of Neurontin, an epilepsy drug, for more than a dozen unapproved uses. Some experts think the practice continues to grow, even as the best journals take steps to prevent it.